Drug
Interleukin 1 Receptor Antagonist Protein clinical trials
Also written Anakinra and Kineret.
- studies test it
- 169
- open now
- 26
- in phase 3
- 35
- first study started
- 2000
Keep track of what changes. Save the Interleukin 1 Receptor Antagonist Protein studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
166 studies that test it; most in 2020 (25)
| Year | Studies |
|---|---|
| 2000 | 1 |
| 2001 | 1 |
| 2002 | 2 |
| 2003 | 3 |
| 2004 | 2 |
| 2005 | 2 |
| 2006 | 2 |
| 2008 | 5 |
| 2009 | 3 |
| 2010 | 2 |
| 2011 | 11 |
| 2012 | 6 |
| 2013 | 6 |
| 2014 | 11 |
| 2015 | 4 |
| 2016 | 10 |
| 2017 | 11 |
| 2018 | 5 |
| 2019 | 11 |
| 2020 | 25 |
| 2021 | 8 |
| 2022 | 9 |
| 2023 | 7 |
| 2024 | 3 |
| 2025 | 5 |
| 2026 | 11 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 6
- Phase 1
- 41
- Phase 2
- 105
- Phase 3
- 35
- Phase 4
- 9
- No phase
- 11
What it is tested for
Each study’s main condition, where its own words name it.
- COVID-19
- 13
Who runs them
Industry 15 · Other 154
Virginia Commonwealth University (16) · Assistance Publique - Hôpitaux de Paris (10) · University Hospital, Basel, Switzerland (8) · Radboud University Medical Center (8) · Hellenic Institute for the Study of Sepsis (7) · Amgen (7) · Swedish Orphan Biovitrum (6) · University of California, San Diego (4)
Often tested with
Tested in the same studies.
Tocilizumab (12) · Baricitinib (4) · Empagliflozin (3) · Dexamethasone (3) · Hydroxychloroquine (3) · Adalimumab (2) · Ustekinumab (2) · Secukinumab (2)
Studies
Open first, then newest update. How each study uses Interleukin 1 Receptor Antagonist Protein is read from its arms, and is right about nine times in ten.
Testing it · 169
- Anakinra for Prevention of Poor Graft Function in MDS Allo-HSCTNot yet recruitingPhase 1/2Ruijin HospitalNCT07888348Written as Anakinra
- Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket TrialRecruitingPhase 2Assistance Publique - Hôpitaux de ParisNCT06381661Written as Anakinra
- Advancing Reperfusion Therapy for Ischemic Stroke: Safety and Efficacy of Anakinra for Futile Reperfusion Following Endovascular Treatment in Patients With Acute Ischemic StrokeRecruitingPhase 2Beijing Tiantan HospitalNCT07423975Written as High-dose Anakinra
- Chemotherapy + Anakinra in Patients With Pancreatic Adenocarcinoma (PDAC)RecruitingPhase 2Baylor Research InstituteNCT04926467Written as Anakinra
- "IL-1β Blockade to Prevent Immunothrombosis in Recipients of a Pancreatic Organ"RecruitingPhase 1/2Nantes University HospitalNCT07503834Written as Anakinra 100Mg/0.67Ml Inj Syringe
- Adding Anakinra and Tocilizumab to Nivolumab and Ipilimumab for the Treatment of Melanoma Patients 50 Years of Age or OlderNot yet recruitingPhase 1University of Southern CaliforniaNCT07838974Written as Anakinra
- BRIDGE - Blocking Receptor of IL-1β for Donor Graft Edema ReductionNot yet recruitingEarly Phase 1Northwestern UniversityNCT07410312Written as Anakinra
- Anakinra Rescue Treatment for Moderate Asthma Attacks (ARTMA)Not yet recruitingPhase 1University of North Carolina, Chapel HillNCT07600190Written as Anakinra 100 Mg/0.67 Ml Inj Syringe
- Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder ArthroplastyRecruitingPhase 2NYU Langone HealthNCT07138898Written as Anakinra
- Anakinra for the Treatment of Postprandial Hypoglycemia in a Patient With Total Gastrectomy and End-Stage Renal DiseaseNot yet recruitingPhase 2Marc DonathNCT07580079Written as Anakinra (interleukin-1 receptor antagonist)
- Randomised Evaluation of COVID-19 TherapyRecruitingPhase 3University of OxfordNCT04381936Written as Anakinra
- Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear DiseaseRecruitingPhase 2Northwell HealthNCT03587701Written as Anakinra 100Mg/0.67Ml Inj Syringe (Period 1)
- Targeted Reversal of Inflammation in Pediatric Sepsis-induced MODSRecruitingPhase 2/3Nationwide Children's HospitalNCT05267821Written as Anakinra
- ANAKINRA IN THE TREATMENT OF PEDIATRIC ACUTE MYOCARDITISNot yet recruitingPhase 3Assistance Publique - Hôpitaux de ParisNCT07371689Written as Anakinra, KINERET®
- Biologic Therapy to Prevent Osteoarthritis After ACL InjuryRecruitingEarly Phase 1University of California, Los AngelesNCT03968913Written as Anakinra injection
- Safety and Efficacy of Anakinra Treatment for Patients With Post Acute Covid SyndromeRecruitingPhase 2/3Hellenic Institute for the Study of SepsisNCT05926505Written as Anakinra 149 MG/ML Prefilled Syringe [Kineret]
- Anakinra Pilot 2 - A Study to Optimise Dose and Route of Administration of Anakinra in Preterm InfantsRecruitingPhase 2Monash Medical CentreNCT07254000Written as Anakinra (Kineret®)
- Randomized Controlled Trial in Patients on Long-term Colchicine With Colchicine-resistant Familial Mediterranean Fever (FMF) to Evaluate the Efficacy of On-demand Anakinra Treatment for Painful Attacks in Patients Who Refuse Continuous Daily TherapyRecruitingPhase 3Assistance Publique - Hôpitaux de ParisNCT06336733Written as ANAKINRA
- Immunomodulatory Effects of Dexamethasone, Tocilizumab and Anakinra During Experimental Human EndotoxemiaRecruitingPhase 4Radboud University Medical CenterNCT06624436Written as Anakinra
- Non Inferiority KawasakI Trial With AnakinraNot yet recruitingPhase 4Meyer Children's Hospital IRCCSNCT06697431Written as Anakinra
See all 169 studies that test Interleukin 1 Receptor Antagonist Protein →
Given in every arm · 3 — Interleukin 1 Receptor Antagonist Protein is usual care beside what is tested
- Capecitabine-based Chemoradiotherapy in Combination With the IL-1 Receptor Antagonist Anakinra for Rectal Cancer PatientsCompletedPhase 1Goethe UniversityNCT04942626Written as Kineret 100 MG in 0.67 ML Prefilled Syringe
- Stem Cell Mobilization (Plerixafor) and Immunologic Reset in Type 1 Diabetes (T1DM)CompletedPhase 1/2University of AlbertaNCT03182426Written as Anakinra
- A Study of CART-PSMA-TGFβRDN in Patients With Metastatic Castration Resistant Prostate CancerTerminatedPhase 1Tceleron Therapeutics, Inc.NCT04227275Written as Anakinra
As the comparator · 4 — what is tested is compared with Interleukin 1 Receptor Antagonist Protein
- COMparison Between Anakinra and Tocilizumab in NORSE - "COMBAT-NORSE"Not yet recruitingPhase 3Yale UniversityNCT07281027Written as Anakinra
- A Study of JNJ-77474462 in Healthy ParticipantsCompletedPhase 1Janssen Research & Development, LLCNCT04544813Written as Anakinra
- A Dose-Block Randomized, Placebo Controlled (Double-blind), Active Controlled(Open-label), Dose-escalation StudyCompletedPhase 1Handok Inc.NCT02175056Written as Kineret(Anakinra)
- The SPECTRA StudyTerminatedPhase 2AmgenNCT00537667Written as anakinra
Codes
What other systems call Interleukin 1 Receptor Antagonist Protein · ClinicalTrials.gg INT008888
- MeSH (NLM) D053590Interleukin 1 Receptor Antagonist ProteinConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 9013DUQ28KANAKINRAConfirmed FDA, NLM
- RxNorm 72435One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D053590 | Interleukin 1 Receptor Antagonist Protein | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 9013DUQ28K | ANAKINRA | Confirmed FDA, NLM |
| RxNorm | 72435 | — | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.